Latest news with #NiftyHealthcare
News18
01-08-2025
- Automotive
- News18
From Auto To Pharma: India's Key Sectors Most Exposed To Trump's 25% Tariffs
Last Updated: Analysts expect textiles, automobiles, oil & gas, and pharmaceuticals to be the most vulnerable to these measures All major sectoral indices, barring FMCG and media, ended lower on Thursday as investor sentiment weakened after US President Donald Trump announced a 25% tariff on Indian goods starting August 1, along with additional non-tariff penalties on crude oil purchases from Russia. Analysts expect textiles, automobiles, oil & gas, and pharmaceuticals to be the most vulnerable to these measures. The textile sector is likely to be among the hardest hit, given the US is its biggest market. 'Margins are expected to take a hit till global trade stabilises," said Prerna Jhunjhunwala, VP equity research (textile and retail), Elara Capital. Shares of Vardhman Textiles and Kitex Garments slumped 5% each, while Gokaldas Exports shed 4.5%. Indo Count Industries and Welspun Living also lost 4% apiece. Sunny Agrawal, head of fundamental equity research, SBICAPS Securities, noted that 'textiles and gems & jewellery stocks are expected to see the most adverse impact due to their high dependence on the US." Automobiles The impact of tariffs on the auto sector remains less clear, as automobiles were already subject to 25% levies under the earlier round of tariff hikes. Analysts believe domestic-focused auto companies may remain largely insulated, but firms with significant US exposure could face headwinds. The Nifty Auto index slipped as much as 1.5% intraday before closing 0.4% lower. Balkrishna Industries fell 2.8%, Bharat Forge 2.3%, while Exide Industries, Samvardhana Motherson International and MRF closed over 1% lower. However, Emkay Global said the sector is 'better placed than feared" since India exports very few vehicles to the US, and auto component makers could benefit if tariffs hit rivals in China, Canada and Mexico. Oil & Gas The Nifty Oil & Gas index declined 1.5%, with 14 of the 15 constituent stocks ending in the red. Mahanagar Gas dropped 4.1%, Adani Total Gas 3.4% and Gujarat State Petronet 2.8%. Shares of IOC, Hindustan Petroleum, GAIL, Oil India and BPCL fell between 1.5% and 2.5%. 'Investors are factoring in supply constraints due to US sanctions on Russian crude purchases by China and India, along with additional penalties on India's Russian oil imports," said Swarnendu Bhushan, co-head of institutional research at Prabhudas Lilladher. He added that higher crude prices could weigh on gross marketing margins of oil marketing companies. Pharmaceuticals Pharma stocks also weakened, with the Nifty Pharma index falling 1.3% and the Nifty Healthcare index down 1.1%. The US is the biggest market for Indian drugmakers, raising concerns about potential fallout. 'In the absence of overnight alternatives for generic drug makers, the US is unlikely to impose tariffs on pharma, as healthcare costs there would surge significantly," said Agrawal. Still, he noted that despite Washington's push for domestic manufacturing, questions remain over the viability of producing at scale in the US. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
25-07-2025
- Business
- Business Standard
India-UK trade deal fails to lift stocks as earnings concerns dominate mkts
The much-anticipated signing of the Comprehensive Economic and Trade Agreement (CETA) between India and the UK did little to buoy Indian equity markets, as a broad sell-off overshadowed sector-specific optimism. While companies across textiles, pharmaceuticals, jewellery, automotive, and agriculture are positioned to benefit from tariff reductions under CETA, most stocks in these sectors closed lower on Friday. The decline was driven by pervasive concerns over weak earnings, which sent the Nifty Smallcap 100 index down by more than 2 per cent. Several sectors are poised for long-term growth from CETA; however, they did not see immediate stock gains as sentiment remained risk-averse, with investors focusing on disappointing earnings. Jasani added that the corporate results will be the immediate trigger for market movement. "The first batch of results is not very positive, and one has to see how the rest of the listed universe fares," he said. The Nifty Healthcare index stood out, rising 0.7 per cent—primarily fueled by a 3.2 per cent surge in Cipla. Healthcare and pharma stocks were the only Nifty sectoral indices to end in positive territory. Domestic liquor shares, particularly Som Distilleries & Breweries, came under pressure due to fears that CETA could intensify competition by easing market access for international brands. Despite short-term market weakness, analysts remain optimistic about companies well-positioned in export-oriented sectors, as they stand to realise gains as tariff reductions take effect and trade flows gradually increase. "The stocks will react to the earnings, and these benefits will need to be reflected in terms of revenue and profit growth. Moreover, the India-US trade deal is the most anticipated event," said Pramod Gubbi, founder of Marcellus Investment Managers.
Mint
23-05-2025
- Business
- Mint
Sensex, Nifty 50 rise 1% — 10 key highlights from Indian stock market today
Indian equity markets staged a sharp rebound on Friday, May 22, bouncing back from Thursday's steep sell-off, as gains in technology and fast-moving consumer goods (FMCG) sectors led a broad-based rally. The strong recovery was powered by upbeat corporate earnings sentiment and a softening in US Treasury yields, which improved risk appetite across global equities. The benchmark Sensex surged 769 points, or 0.95 percent, to close at 81,721, while the Nifty 50 climbed 243 points, or 1 percent, to settle at 24,853, reclaiming the 24,800 mark. Despite Friday's sharp gains, both indices ended the week slightly lower, logging weekly losses of more than 0.65 percent. The market's recent volatility has been driven by global uncertainties, including developments in US-India trade relations, concerns over the US fiscal outlook, and currency market fluctuations. These factors have kept investors on edge, leading to choppy trading sessions throughout the week. However, Friday's rebound was aided by short-covering and value-buying, with investors betting on long-term tailwinds for the Indian economy. Analysts noted that expectations of stable earnings growth, the possibility of rate cuts, and a normal monsoon are keeping sentiment buoyant despite short-term global headwinds. With positive domestic fundamentals and improving macro cues, market participants are hopeful for a more sustained uptrend, although global triggers may continue to influence direction in the near term. Shares of Eternal (up 3.6 per cent), HDFC Life (up 3.28 per cent), Jio Financial (up 2.5 per cent), PowerGrid (up 2.46 per cent), and ITC (up 2.32 per cent) ended as the top gainers. Sun Pharma, Grasim, Bharti Airtel, and Bharat Electronics were the only losers in the index. Broader indices also participated in the rally. The Nifty Midcap 100 advanced 0.67 percent, while the Nifty Smallcap 100 outperformed, rising 0.80 percent to finish at 17,643. On the sectoral front, the Nifty FMCG and Nifty Private Bank indices emerged as standout performers in Friday's session, posting gains of 1.63 percent and 1.08 percent, respectively. The rally in these sectors contributed significantly to the overall market rebound. Other key indices also closed in positive territory, with IT, Financial Services, Metal, PSU Bank, Oil & Gas, and Realty all ending higher, notching up gains of up to 0.95 percent. On the flip side, the Nifty Pharma and Nifty Healthcare indices were the only two sectoral laggards. Nifty Pharma slipped by 0.41 percent, while Nifty Healthcare edged lower by a marginal 0.01 percent, capping an otherwise broad-based recovery across the market. Reliance Power (42.91 crore share), Tata Teleservices (11.91 crore shares), and Eternal (4.21 crore shares) were the most active stocks in terms of volume on the NSE. Eternal and Reliance Power were the two stocks that jumped over 15 per cent on the NSE. Some 93 stocks, including Honasa Consumer, Apollo Pipes, Skygold, and Emcure Pharma, hit their upper circuits in intraday trade on the NSE. On the other hand, 48 stocks, including Orient Tech, Raymond, 63 Moons Tech, and Focus Lighting, hit their lower circuits during the session. As many as 1,731 stocks advanced, while 1,132 declined and 84 remained unchanged on the NSE. HDFC Asset Management Company, Max Financial, APL APollo Tubes, EID Parry, MRF, Solar Industries and Dalmia Bharat were among the 50 stocks that hit their 52-week highs in intraday trade on the NSE. On the flip side, Aditya Birla Fashion, Protean EGov Tech, and Chembond Chemicals, were among the 17 stocks that hit their 52-week lows during the session. "The index has moved higher after finding support at the 21-day EMA. Broadly speaking, the Nifty appears to be consolidating within the range of 24,700–25,000. The short-term trend remains positive, with momentum likely to strengthen above 25,000. A decisive breakout above this level could give the bulls an upper hand and potentially trigger a rally towards 25,250–25,350. On the downside, the index has support at 24,700; a break below this level could attract bearish bets," Rupak De, senior technical analyst, LKP Securities. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
19-05-2025
- Business
- Economic Times
Mutual funds bet big on healthcare stocks after Trump's tariff pause. Is the danger really over?
Live Events Mutual funds with highest exposure in health stocks Returns snapshot Outlook (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Donald Trump 's 90-day pause on reciprocal tariffs announced on April 9, 2025, brought much-needed stability to stock markets and lifted sentiment in the pharma and healthcare sectors, which had been clouded by pharmaceutical sector found itself in a unique position, having received exemptions in the initial tariff announcements which kicked-in on April 2, though no clarity on what lay ahead. Between April 2 and April 9, the Nifty Healthcare index had declined by over 3%, or nearly 1,300 the Nifty Healthcare index staged a strong rebound following the pause, rising 7% or around 2,650 points over the remaining 12 trading sessions of the month. This recovery was accompanied by notable institutional activity, with mutual funds increasing their holdings in 11 healthcare stocks in April compared to was also among the sectors where MF ownership was higher by over 1% versus the sector's weight in the BSE 200 to a Motilal Oswal report, 17 funds were over-owned and MFs weight on the sector stood at 7.6% in April, behind private banks (18.9%), technology (8.3%) and automobiles (8%). Meanwhile, the healthcare sector in BSE 200 stands at 5.4%, the report MoM buying of 11.43% in April was seen in midcap stock Syngene International . It was followed by Glenmark Pharmaceuticals Dr. Reddy's Laboratories and Laurus Labs where mutual funds added stake by 7.63%, 6.05% and 3.85%, like Lupin, Aurobindo Pharma, Divi's Laboratories, Sun Pharmaceutical Industries, Abbott India, Ipca Laboratories and Biocon also saw mutual fund action towards the buying healthcare stocks also went under the hammer and saw a sell-off. These were Zydus Lifesciences Torrent Pharmaceuticals , Max Healthcare Institute, Mankind Pharma, Granules India, Fortis Healthcare, Cipla, Apollo Hospitals Enterprise and Alkem selling was highest in Torrent Pharma and Zydus Lifesciences at 8.34% and 4.87%, respectively. The next in the pecking order were Granules, Apollo and Mankind where MFs sold 3.89%, 3.64% and 3.61%. The others saw a sell-off between 1.67% and 0.46%.Sumit Bhatnagar, Fund Manager Equity at LIC Mutual Fund said that the healthcare sector often remains resilient due to the essential nature of its services and products and innovations and an aging population continue to drive demand. However, the potential impact of Trump's tariffs on the healthcare sector is a valid concern in his view and tariffs could increase costs for healthcare companies which could affect their profitability. "These increased costs might be passed on to consumers or could lead to reduced margins for healthcare companies," he told and Quant top the list with holdings of 11.5% and 11.1%, respectively and are followed by Axis MF (10.4%), Mirae (9.7%), HDFC MF (9.1%) and Sundaram MF (8.4%).The lowest holdings are for SBI MF (5.1%), MOFSL (5.5%) and UTI MF (6.1%).Nifty Healthcare index's 1-year returns stand at 17%, outperforming Nifty which has returned 12% in the same continued to show trust on Syngene in April despite a 6% drop in share price over a 1-year period. Meanwhile, mutual funds sold shares in laggards Zydus Lifesciences and Alkem which have fallen 14% and 2% in the past 12 remains the best performer in the pack with 60% returns and MFs added stakes in April (1.13%) and March (2%). Glenmark and Laurus, which also saw significant MF action, have returned robust 44% and 36% Abbott, Sun Pharma and Biocon have also given double-digit returns in the same period while IPCA, Aurobindo and Dr. Reddy's have delivered single-digit funds booked partial profits in stocks like Fortis Health, Max Health, Granules, Mankind and Torrent Pharma whose 1-year returns stand in the range of 21% and 56%. Apollo Hospitals has yielded 18% returns while Cipla has been an underperformer with just 6% sector is again in the eye of the storm as Trump has signed an executive order to bring the prices for prescription (Rx) drugs in line with other developed nations. The order institutes the Most-Favoured-Nation (MFN) price model for drugs as a ceiling which means the US will pay for drugs at the same levels as the lowest paid by other countries."The policy initiatives, if implemented fully, may lead to increased compliance/operational cost for foreign manufacturers, including those in India. We expect generic pharma to continue to underperform due to uncertainty," Nuvama Institutional Equities said in a note. It prefers Ajanta Pharma, Torrent Pharma and Divi's Securities sees the generic companies unlikely having any impact, though it expects Sun Pharma with its specialty business in the US, to see some impact of MFN price ceiling for a few of its products. JM Financial sees over 20% growth visibility for hospitals and CDMO for the next 4-5 years. Amongst the hospitals, it likes Max Healthcare, Aster DM and Fortis while Piramal Pharma and One Source in UBS expects healthcare to outperform Nifty over the next 12-month period as the Zurich-based brokerage reiterated its positive stance on Nifty, seeing an 8% upside with a target of 26,000. In a note of caution on generic pharma export names, it expects earnings downgrades starting in 2HFY26.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Time of India
19-05-2025
- Business
- Time of India
Mutual funds bet big on healthcare stocks after Trump's tariff pause. Is the danger really over?
Live Events Mutual funds with highest exposure in health stocks Returns snapshot Outlook (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Donald Trump 's 90-day pause on reciprocal tariffs announced on April 9, 2025, brought much-needed stability to stock markets and lifted sentiment in the pharma and healthcare sectors, which had been clouded by pharmaceutical sector found itself in a unique position, having received exemptions in the initial tariff announcements which kicked-in on April 2, though no clarity on what lay ahead. Between April 2 and April 9, the Nifty Healthcare index had declined by over 3%, or nearly 1,300 the Nifty Healthcare index staged a strong rebound following the pause, rising 7% or around 2,650 points over the remaining 12 trading sessions of the month. This recovery was accompanied by notable institutional activity, with mutual funds increasing their holdings in 11 healthcare stocks in April compared to was also among the sectors where MF ownership was higher by over 1% versus the sector's weight in the BSE 200 to a Motilal Oswal report, 17 funds were over-owned and MFs weight on the sector stood at 7.6% in April, behind private banks (18.9%), technology (8.3%) and automobiles (8%). Meanwhile, the healthcare sector in BSE 200 stands at 5.4%, the report MoM buying of 11.43% in April was seen in midcap stock Syngene International . It was followed by Glenmark Pharmaceuticals Dr. Reddy's Laboratories and Laurus Labs where mutual funds added stake by 7.63%, 6.05% and 3.85%, like Lupin, Aurobindo Pharma, Divi's Laboratories, Sun Pharmaceutical Industries, Abbott India, Ipca Laboratories and Biocon also saw mutual fund action towards the buying healthcare stocks also went under the hammer and saw a sell-off. These were Zydus Lifesciences Torrent Pharmaceuticals , Max Healthcare Institute, Mankind Pharma, Granules India, Fortis Healthcare, Cipla, Apollo Hospitals Enterprise and Alkem selling was highest in Torrent Pharma and Zydus Lifesciences at 8.34% and 4.87%, respectively. The next in the pecking order were Granules, Apollo and Mankind where MFs sold 3.89%, 3.64% and 3.61%. The others saw a sell-off between 1.67% and 0.46%.Sumit Bhatnagar, Fund Manager Equity at LIC Mutual Fund said that the healthcare sector often remains resilient due to the essential nature of its services and products and innovations and an aging population continue to drive demand. However, the potential impact of Trump's tariffs on the healthcare sector is a valid concern in his view and tariffs could increase costs for healthcare companies which could affect their profitability. "These increased costs might be passed on to consumers or could lead to reduced margins for healthcare companies," he told and Quant top the list with holdings of 11.5% and 11.1%, respectively and are followed by Axis MF (10.4%), Mirae (9.7%), HDFC MF (9.1%) and Sundaram MF (8.4%).The lowest holdings are for SBI MF (5.1%), MOFSL (5.5%) and UTI MF (6.1%).Nifty Healthcare index's 1-year returns stand at 17%, outperforming Nifty which has returned 12% in the same continued to show trust on Syngene in April despite a 6% drop in share price over a 1-year period. Meanwhile, mutual funds sold shares in laggards Zydus Lifesciences and Alkem which have fallen 14% and 2% in the past 12 remains the best performer in the pack with 60% returns and MFs added stakes in April (1.13%) and March (2%). Glenmark and Laurus, which also saw significant MF action, have returned robust 44% and 36% Abbott, Sun Pharma and Biocon have also given double-digit returns in the same period while IPCA, Aurobindo and Dr. Reddy's have delivered single-digit funds booked partial profits in stocks like Fortis Health, Max Health, Granules, Mankind and Torrent Pharma whose 1-year returns stand in the range of 21% and 56%. Apollo Hospitals has yielded 18% returns while Cipla has been an underperformer with just 6% sector is again in the eye of the storm as Trump has signed an executive order to bring the prices for prescription (Rx) drugs in line with other developed nations. The order institutes the Most-Favoured-Nation (MFN) price model for drugs as a ceiling which means the US will pay for drugs at the same levels as the lowest paid by other countries."The policy initiatives, if implemented fully, may lead to increased compliance/operational cost for foreign manufacturers, including those in India. We expect generic pharma to continue to underperform due to uncertainty," Nuvama Institutional Equities said in a note. It prefers Ajanta Pharma, Torrent Pharma and Divi's Securities sees the generic companies unlikely having any impact, though it expects Sun Pharma with its specialty business in the US, to see some impact of MFN price ceiling for a few of its products. JM Financial sees over 20% growth visibility for hospitals and CDMO for the next 4-5 years. Amongst the hospitals, it likes Max Healthcare, Aster DM and Fortis while Piramal Pharma and One Source in UBS expects healthcare to outperform Nifty over the next 12-month period as the Zurich-based brokerage reiterated its positive stance on Nifty, seeing an 8% upside with a target of 26,000. In a note of caution on generic pharma export names, it expects earnings downgrades starting in 2HFY26.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
